Drug Pipeline
... More
Briefing
“Breakthrough Therapy”
17 result(s)
Care Management
The Promise and Questions of Aducanumab
Biogen’s new Alzheimer’s drug may be changing the treatment landscape, but lingering questions remain. More
Commentary
Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Cost Management
CVS Health offers payors a new stop-loss program and installment payment plan to help mitigate the large one-time impact of costly gene therapies. These approaches are part of... More
Briefing
Drug Pipeline
Updates on the robust gene therapy pipeline from CVS Health pipeline team to help payors stay abreast of this very important emerging category. More
Briefing
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's... More
Feature
Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
Cost Management
Gene therapies have the potential to relieve tremendous suffering for patients with genetic disorders and together we can find ways to ensure these treatments are accessible for... More
White Paper
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature